

## CURRICULUM VITAE

Nume: RODICA-MARICELA ANGHEL

Adresa de contact: Institutul Oncologic Bucuresti "Prof. Dr. Al. Trestioreanu"  
Tel/fax: 021-2271400; 021-3183262  
e-mail: rodicamanghel@gmail.com

Titlul stiintific:

Profesor, Disciplina de Oncologie, Universitatea de Medicina si Farmacie "Carol Davila" Bucuresti

Locul de muncă actual și funcția:

Director Departament 8 (Oncologie, Radiologie-Imagistica si Hematologie) - UMF Carol Davila Bucuresti - 2016

Sef Disciplina de Oncologie – 2002 - prezent

Vice-Presedinte a Comisiei Nationale de Oncologie Medicala, Radioterapie si Chirurgie Oncologica a Ministerului Sanatatii Publice - 2012

Director - Centrul de Cercetare Oncologie Fundamentala si Clinica - U.M.F. "Carol Davila" Bucuresti

Manager – Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti - 2002-2006; 2009-2013

Educatie profesionala, cursuri si specializari:

1979	Absolventa a Facultatii de Medicina, Bucuresti, Romania
1980-1985	Rezidentiat in radiologie si radioterapie, Bucuresti
1994	Stagiu de pregatire postuniversitara la centrul de Lupta contra Cancerului „Alexis Vautrin”, Nancy, Franta
1998	Radiation alone or combined with chemotherapy in carcinoma of the nasopharinx” condus de Carlos A Perez, Madrid, Spania
1998	“Highlights in oncology surgery” condus de PhD Charles Balch, Bucuresti, Romania
1998	“Bifosfonatii de la laborator la pacient”,
1999	Cancerul pancreatic ; pancreatita cronica” cursuri in cadrul Inst National de Perfectionare postuniversitara a Medicilor si Farmacistilor Bucuresti
1999	Stagiu de pregatire postuniversitara la spitalul „Hotel Dieu de Quebec” Canada
2000	Cancerul tubului digestiv superior – esofag, stomac, „Actualitati in chirurgia ficatului”, cursuri in cadrul Inst. National de Perfectionare postuniversitara a Medicilor si Farmacistilor Bucuresti
2001	Stagiu de pregatire postuniversitara la „Donnau Hospital”, Viena, Austria
2001	Expert Evaluator pentru Competenta si Tinuta Stiintifica in Activitatea de Evaluare a Cercetarii din Invatamantul Superior – CNC SIS
2004	Competenta in Managementul Serviciilor de Sanatate

- 2005 Curs - Vienna School of Clinical Research Introduction to Good Clinical Practice Basics of GCP implementation in clinical trials
- 2006 Facultatea de Administratie publica – Scoala Nationala de Studii Politice si Administrative – Studii Academice Postuniversitare 2003 – 2006
- 2010 OECI Accreditation Training Course – June 2010, Budapest, Hungary
- 2010 UMF “Iuliu Hatieganu” Cluj-Napoca/Medica Academica/British Medical Journal – Curs deschis la distanta , 01.02.2010 – 31.12.2010
- 2012 Advanced GCP for Clinical Research Professionals – ICR (The Institute of Clinical Research)
- 2012 Varian Medical Systems International AG – Oncology Information System Training – 27 February-1 March 2012
- 2012 IAEA National Training Course on the implementation of Quality Management Systems in a Radiotherapy Centre 12-14 December 2012 – Bucharest, Romania (ROM6016)
- 2013 IAEA National Training Course on implementation of quality Management Systems in a Radiotherapy Center – Bucharest, 15-17 May
- 2013 ESTRO course of Advanced Treatment Planning – Utrecht, Olanda, 8-12 Septembrie 2013
- 2013 ESTRO course – Target Volume Determination – From Imaging to Margins – Ljubljana, Slovenia, 9-13 June 2013
- 2013 Rapidarc/VMAT Course/Training - Université Catholique de Louvain, Brussels, Belgium, 16 – 26 September 2013
- 2013 RER6022/9001/01 Workshop on Education of Radiation Therapists in Europe: Current Situation and the Way Forward – Vienna, Austria, 27–29 Nov.2013
- 2013 Advanced GCP for Clinical Research Professionals - Decembrie 2013, Bucuresti
- 2015 Elekta 7th European Users’ Meeting – Adapting and innovating clinical solutions in a changing word – Monte Carlo, 3-4 Septembrie 2015

Teza de doctorat:

- 1995 “Noi posibilități de optimizare a tratamentului cancerului colului uterin” – Institutul Oncologic Bucuresti

Titluri universitare:

- 1982 – 1992 Asistent Universitar – Universitatea de Medicina si Farmacie “Carol Davila”, Bucuresti
- 1992 – 1997 Sef de Lucrari - Universitatea de Medicina si Farmacie “Carol Davila”, Bucuresti
- 1997 – 2002 Conferentiar - Universitatea de Medicina si Farmacie “Carol Davila”, Bucuresti
- 2002 – prezent Profesor - Universitatea de Medicina si Farmacie “Carol Davila” Bucuresti
- 2006 – prezent Profesor – Conducator de Doctorate - Universitatea de Medicina si Farmacie “Carol Davila” Bucuresti;

## Experienta profesionala

1982-1985	medic secundar spitalul "I. Cantacuzino";
1985	medic specialist radiolog spitalul "I. Cantacuzino";
1986	medic specialist oncologie-radioterapie spitalul "I. Cantacuzino";
1990	medic primar radiolog Inst. Oncologic București;
1991	medic primar oncologie radioterapie Inst. Oncologic București;
2002	medic primar oncologie chimioterapie Inst. Oncologic Bucuresti

## Premiere medicale in Romania:

- Tratamentul multimodal in cancerul pancreatic – interventie chirurgicala, radioterapie externa, brahiterapie, chimioterapie
- Radioterapia stereotaxica in tumorile cerebrale
- Iradierea corporeala totala in pregatirea transplantului medular
- Iradierea externa conformationala a diferitelor localizari
- Iradierea interstitiala in cancerul de prostata cu implante permanente de I125.
- Iradiere IMRT

## Studii clinice si contracte de cercetare:

### *Contracte de cercetare*

- Contract de cercetare cu Academia Romana (1997): Noi posibilitati de optimizare a tratamentul cancerului de col uterin"
- Contract cu Inst.Elenic Atena :” Leziuni precursorare(de granita) in cancerul mamar”
- Contract nr.658/1996 cu MCT „Rolul chimioterapiei avand ca pivot o sare de platina in tratamentul unor cancere ale colului uterin rezistente la radioterapie”
- Contract nr.010 in programul VIASAN cu tema „ Tehnologii noi de tratament in cancere compacte (solide) folosind droguri citostatice in doze mari cu suport transplant de celule stem hematopoetice”;
- Contract cu nr. 012 in programul VIASAN cu tema „Corelatii intre nivelul proteinelor receptoare pentru estrogeni si progesteron si expresia unor gene supresoare ( p53, BRCA1 , BRCA2) in cancerul mamar”-
- „Tratamentul peste 6 luni al anemiei va schimba perspectiva in ceea ce priveste supravietuirea la pacientii cu cancer din Europa?”, tema de cercetare internationala, expert principal Prof,Heinz Ludwig, Austria, 2001;
- „Studiu unicentric deschis pentru folosirea Eprexului in oncologie la pacientele cu cancer al colului uterin”, tema efectuata in colaborare cu firma Janssen Cilag 2000
- Contract de cercetare European Cancer Health Indicator Project - EUROCHIP 2 – proiect international
- BNCT. Studiul, cercetarea si abordarea in clinica oncologica a radioterapiei cu neutroni captati de catre Bor-10 – VIASAN 5 (2005) - Director de proiect
- RADMEDMAG. Cercetari de diagnoza preventiva si reducerea efectelor radiatiilor ionizante asupra tesuturilor sanatoase – VIASAN 19 (2005)
- TARD. Dezvoltarea si testarea unui sistem automat de analiza a riscului, diagnoza si decizie pentru asistarea actului medical – INFOSOC 12 (2005)

- BIOMARC. Biomolecule radiomarcate pentru tratamentul tinit al cancerului si inhibarea angiogenezei – VIASAN 26 (2005)
- RADMED. Terapii inovative in tratarea unor forme de neoplasme prin actiunea sinergica a unor compusi bioactivi, electroni accelerati si microunde – PC-D01-PT11-827 (2005)
- Noi tinte celulare si moleculare in terapia cu orientare spre pacient a tumorilor maligne. O abordare genomica si proteomica – PC-D01PT11-798 (2005)
- BIOSTROMA - Studii biomoleculare pentru factori de prognostic in tumorile stromale gastrointestinale – VIASAN (2005)
- GENOPACT – Investigarea genomica si proteomica a cancerului de pancreas si corelarea datelor cu parametrii clinico-patologici – VIASAN 66 (2005)
- LASOPMED Metode laser,optice si spectrale pentru detectia precoce a modificarilor patologice in bio-tesuturi VIASAN 4/2005
- CORDCEL Noi strategii de vterapie celulara prin folosires de progenitori hematopietici din sangele de cordon ombilical BIOTECH 85/2005
- ACMLU Terapia tintita cu doze mari în cancerule pulmonare, ovariene, pancreatice si colorectale cu anticorpi monoclonali radioactivi marcati cu Lu si suport de celule stem - VIASAN 122 (2006) Director de proiect
- MELASPOT Procesarea antigenelor tumorale in melanomul malign. Identificarea de noi biomarkeri pentru diagnostic si studii preclinice de investigare a potentialului terapeutic CERES 2-CEEX 06-11-4/ 25.07.06
- CAVEEX Expresia caveolinelor 1,2 si 3 in cancerule pancreatice; tinte moleculare in diagnostic si terapie BIOTECH 64/2006
- LIVERSTEM Potentialul therapeutic al celulelor stem hematopietice in afectiunile hepatice BIOTECH 65/2006
- PACAGENTER Profile genice induse de suptesia transcriptionala a ETS 1 in cancerul de pancreas BIOTECH 62/2006
- MEDINANOLAS Interferente farmacologice ale unor produse fitoterapeutici cu agenti terapeutici conventionali; modele predictive in optimizarea designului terapeutic modern BIOTECH 86/2006
- CNCSIS (contracte si platforme medicale): Platforma “George Emil Palade” (medicina translationala cu scopul de a transforma datele din cercetare fundamentala in cercetare clinica) – Partener in proiect (2006)
- PNII\_11\_005\_ NEOSIM - Sistem inteligent pentru monitorizarea raspunsului la tratament al bolnavilor cu neoplazii in sfera genitala si asistare la stabilirea prognosticului si sperantei de viata a acestora prin analiza modificarilor parametrilor clinici si paraclinici – *responsabil partener*
- PNII\_41\_080\_ NAGANT - 177Lu–Neurotensina, radiofarmaceutic pentru radioterapia tintita a cancerului. Interactii agonist si antagonist de neurotensina cu receptori peptidici implicati in evaluarea radiofarmacologica si radioterapeutica – *responsabil partener*
- Ru-QUIN - Sinteza, caracterizarea și testarea acțiunii biologice a unor noi combinații complexe ale ruteniului, alternativă potențială la terapia cu compuși ai platinei
- FITOMEDAS - Dezvoltarea unui fitoprodus farmaceutic pentru terapia preventivă și curativă a tumorilor mamare benigne și maligne
- RECTTREATMENT - Algoritm de monitorizare al tratamentului multimodal în cancerul de rect, cu impact direct asupra creșterii ratei de supraviețuire și calității vieții bolnavilor – *responsabil partener*

- ANORG-PLANT - Sinteza, caracterizarea și evaluarea potențialului terapeutic al unor noi combinații complexe ale oxovanadiului (IV) cu liganzi naturali – *responsabil partener*
- Program NEW COST BM 0607/ Radionuclide Targeted Therapy, 2007 -2010, Comitetul Roman de Management
- ONCOSTEM – Identificarea și caracterizarea unei subpopulații de celule cu proprietăți de celule stem tumorale în hepatoame și cancere esofagiene și corelarea cu mecanismele de rezistență la tratament (2008)
- ERANET Project no. HEALTH F2-2010-266559: TRANSCAN – ERA\_NET on Translational Cancer Research – 2012 – 2016 - Responsabil partener Institutul Oncologic Prof Dr Al Trestioreanu Bucuresti
- POSDRU/63/3.2/S/20596 - Instruire si preventie pentru o viata sanatoasa – 2010 – 2012 – Responsabil partener UMF Carol Davila Bucuresti
- Dezvoltare de radiofarmaceutice functionale cu tintire specifica pe tip de receptor destinate imagisticii moleculare PET si radioterapiei sistemice – 228/ 2014-2017 – Responsabil partener

#### *IAEA (PROIECTE NATIONALE)*

- ROM6016 - Upgrading Radiotherapy Practice at the Oncology Institute through the Introduction of New Techniques – Coordonator proiect – 2012-2013
- ROM6018 - Enhancing Radiotherapy Services by Establishing a National Dosimetry Audit Facility
- ROM - CONCEPT 2020-2022 - Establishing a National Training Facility to improve Safety and Quality of radiotherapy Services in Romania

#### *IAEA (PROIECTE REGIONALE)*

- RER6022 - The project RER6022 9001, Strengthening Knowledge of Radiation Oncologists and Radiation Therapists.
- RER 6033 - Strengthening Knowledge of Radiation Therapy Professionals (Radiation Oncologists, Medical Physicists and Radiation Therapy Technologists)

#### Studii clinice

1. PC101-EULINT 1 International prophylactic Cranial Irradiation Trial “A multicentre randomised trial of high versus standard doses of prophylactic cranial irradiation in limited small cell lung cancer complete responders”;
2. Contract cu Takeda :” Randomised controlled multicenter comparative study of the efficacy and tolerability of leuprorelin acetat vs. CMF chemotherapy as adjuvant therapy for breast cancer” 1998-1999
3. Studiu clinic de faza III dublu orb, multicentric randomizat la pacientii cu cancer pancreatic local avansat sau metastatic comparativ intre terapia combinata VIRULIZIN plus GEMCITABINE versus Placebo+Gemcitabine – terapie optionala de linia a doua poate include continuarea cu Virulizin sau Placebo singur combinat cu 5\_Fluorouracil;
4. BCIRG 007 (WO 16437) A multicenter phase iii randomized trial comparing docetaxel (taxotere®) and trastuzumab (herceptin®) with docetaxel (taxotere®), carboplatin and trastuzumab (herceptin®) as first line chemotherapy for patients with metastatic breast cancer containing the her2 gene amplification;
5. PAC-RT-03 Paclitaxelul ca radiosensibilizator in cancerul bronhopulmonar fara celule mici (cbfcm) stadiul IIIa (inoperabil) – IIIb;

6. H3E-MC-JMGE Studiu randomizat, dublu-orb, de faza 2 a doua doze de alimta<sup>™</sup> (ly231514, pemetrexed) ca si chimioterapie de prima optiune in cancerul mamar avansat.
7. H3E-MC-JMEN Maintenance Therapy Studiu de faza 3, dublu-orb, controlat placebo, al pemetrexed de intretinere plus cea mai buna asistenta suportiva versus cea mai buna asistenta suportiva imediat dupa tratamentul de inducere pentru cancer pulmonar avansat fara celule mici
8. CECOG/ GIST 1.2.001 Studiu clinic deschis utilizand Glivec la pacienti cu tumori gastrointestinale neoperabile sau metastatice maligne cu c-kit exprimat
9. H3E-MC-JMDV Studiu clinic de faza ½ privind cresterea dozei de Alimta si Cyclophosphamida administrate la fiecare 21 de zile la pacientele cu cancer de san local avansat sau metastatic
10. 3066A1-303-WW Studiu de faza 3 randomizat, controlat placebo, dublu-orb al administrarii orale a CCI-779 in combinatie cu Letrozole versus Letrozole singur ca terapie hormonala de prima linie la femeile postmenopauza cu cancer de san local avansat sau metastatic
11. CECOG/CORE 1.2.001 Studiu de faza II, deschis, randomizat care evalueaza eficacitatea si siguranta folosirii tratamentului cu FOLFOX 6 + CETUXIMAB versus FOLFIRI + CETUXIMAB ca prima linie de tratament la pacientii cu cancer colorectal metastazat.
12. MO18024 Tratament de prima linie cu bevacizumab in combinatie cu chimioterapia in cancerul colorectal metastatic
13. EFC10547 A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
14. H3E-MC-JMHR A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
15. CECOG/CORE 1.2.002 A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + Weekly Cetuximab versus FOLFOX4 + biweekly Cetuximab as first line therapy in patients with k-ras wild-type metastatic colorectal cancer
16. KF5503/15 A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor-related pain
17. EMR 63325 A multi-center phase III randomized, double blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.
18. VANILLA - EFC10547 A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
19. CECOG/BC.1.3.005: -"A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer"
20. BO21990 - A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
21. Celtrion CT-P6 - 3.1 / A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer
22. N°8-79-52014-168 "Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score changes during initiation of Androgen Deprivation Therapy (ADT) with triptorelin 22.5mg in patients with ADVanced prostate cancer (PCa): A phase III, single arm multicentre study".

23. EFC11785 / randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m<sup>2</sup> and at 25 mg/m<sup>2</sup> Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration resistant Prostate cancer Previously Treated With a Docetaxel-Containing Regimen.
24. Efficacy and Safety of long-Term (6 Months) Innohep® Treatment versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT
25. AMG 386 Protocol No. 20090508 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
26. 212082-PCR-3001 - An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy.
27. A Phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
28. A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7,5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit.
29. AMG 20100007 – A phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer
30. LA-EP06-301 – A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta in breast cancer patients treated with myelosuppressive chemotherapy
31. BO25114 – A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer.
32. A single arm, open label phase II, multicentric study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (Roche 2012-2014)
33. MK0517 – A Phase III, Randomized, Double-blind, Active Comparator-Controlled Parallel-Group, Conducted Under In-House Blinding Condition, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
34. V212 Protocol 011 – A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 Adult Patients with Solid Tumor or Hematologic Malignancy
35. M12-895 – A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
36. EFC11784/FIRSTANA – Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m<sup>2</sup> and at 20 mg/m<sup>2</sup> in Combination with Prednisone Every 3

- Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy
37. Randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta in breast cancer patients treated with myelosuppressive chemotherapy - Sandoz LA - EP06 – 301
  38. A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer - JACOB BO25114
  39. A Phase 3, Multicenter, Randomized, Open Label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects with Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer – Amgen 20100007
  40. A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
  41. A double-blind placebo-controlled randomized Phase IIIb trial evaluating the efficacy and safety of standard care +/- continuous bevacizumab treatment following progression of disease (PD) in patients with glioblastoma (GBM) after 1<sup>st</sup> line treatment with radiotherapy, temozolomide and bevacizumab TAMIGA, MO28347 (2013)
  42. The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer, BROCADE, M12-895
  43. AVAGLIO BO21990, studiu de faza 3, randomizat, dublu-orb privind asocierea Bevacizumab cu Temozolomida și radioterapie la pacienții nou diagnosticați cu glioblastom 2010 – 2015
  44. The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer, BROCADE, M12-895
  45. 2011-2015 – investigator în studiul clinic PROSELICA EFC11785, studiu deschis de faza 3, randomizat, care compară Cabazitaxel 20 mg/m<sup>2</sup> și 25 mg/m<sup>2</sup> la fiecare 3 săptămâni, în combinație cu Prednison pentru tratamentul cancerului de prostată metastazat, rezistent la castrare, tratat în prealabil cu Docetaxel
  46. 2011-2015 – investigator în studiul clinic FIRSTANA EFC11784, studiu deschis de fază 3, randomizat, care compară Cabazitaxel la 25 mg/m<sup>2</sup> și 20 mg/m<sup>2</sup> în combinație cu Prednison, la fiecare 3 săptămâni, cu Docetaxel în combinație cu Prednison, la pacienții cu cancer de prostată metastazat, rezistent la castrare, netratați în prealabil cu chimioterapie
  47. 2011-2016 – investigator în studiul clinic V212-011, studiu de fază 3, randomizat, dublu-orb, care compară siguranța și toleranța V212 cu placebo, la administrarea la adulți cu tumori solide (STM) sau afecțiuni maligne hematologice (HM) pentru a determina dacă V212 reduce incidența Herpes zoster la adulți STM sau HM, în comparație cu placebo
  48. 2015-2018 – investigator în studiul clinic NBTXR3-301, studiu randomizat, deschis, de fază II/III, care compară eficiența NBTXR3, prin injecție intratumorală și activare prin radioterapie, versus radioterapia singură la pacienții cu sarcoame de țesuturi moi, local avansate, localizate la nivelul trunchiului sau extremităților



49. Randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta in breast cancer patients treated with myelosuppressive chemotherapy - Sandoz LA - EP06 – 301
50. A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer - JACOB BO25114
51. Phase 3, Multicenter, Randomized, Open Label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects with Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer – Amgen
52. Avelumab in first line Non-Small Cell Lung Cancer, A phase III open label, multicenter trial – investigator principal

Membru al asociațiilor profesionale:

- Societatea Română de Oncologie; Membru in Colegiul National al Societatii
- Presedinte al Societatii Romane de Radioterapie si Oncologie Medicala 2006
- Vicepresedinte al Societatii Romane de Neuro-Oncologie
- Presedinte Societatea Romana de Radioterapie
- Membru in Comitetul Stiintific al EORTC (European Cooperative Oncology Group)
- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- International Society of Geriatric Oncology (SIOG)
- Balkan Union of Oncology (BUON)
- Membru in Anemia Working Group sectia romana
- Vice-Presedinte Comisia de Oncologie a Ministerului Sanatatii 2012
- Membru in Comisia de Transparenta a Ministerului Sanatatii - 2011
- Membru IASGO
- Membru European Society for Radiotherapy and Oncology (ESTRO)
- Membru American Society for Radiation Oncology (ASTRO)

Membru in comitetele redactionale ale unor reviste de specialitate:

Membru in colegiul de redactie al JAMA – sectia romana

Membru in colegiul de redactie a Revistei Societatii Romane de Oncologie

Membru a colegiului de redactie al revistei Radioterapie si Oncologie Medicala

Membru al colectivului de redactie al revistei B.U.O.N

Membru al colectivului editorial al revistei MEMO (Magazine of European Medical oncology)

Lector:

Lector:

- Curs ESMO – Bazele fundamentale in oncologie, 2-4 aprilie 2004, Bucuresti
- Curs ESMO – Tumoriile capului, gatului si toracelui, 30 septembrie – 2 octombrie, 2004 Bucuresti
- Curs ESMO – Combined modality treatment of gynecological malignancy – Rodica Anghel – ESMO SIOG Course – 23-25 june 2005, Bucharest
- Curs ESMO – Tumoriile tractului gastrointestinal, 2006, Bucuresti
- Conferinta anuala OECI 20-22 mai 2004, Berlin
- Regional Coordination and planning meeting on cancer management in TC Europe Member States, Vienna, Austria, 31 ian – 1 feb 2005
- Central European Cooperative Oncology Group (CECOG) Consensus Conference on Medical Treatment of Colorectal Cancer, 31 march 2005, Vienna, Austria
- Curs - Protectia radiologica in radioterapie, 2006
- The 6-th International MTTC Workshop – Rodica Anghel, Chair of the session: Early Clinical Drug Development - 7-8 April 2006, Cracovia, Polonia
- Curs ESMO Targeted therapy and radiation therapy for head and neck cancer – Rodica Anghel, "Molecular targeted therapy in oncology: hopes, facts and further promises" - Bucharest, Phoenicia Grand Hotel, 19 - 21 Aprilie 2007
- CECOG Consensus Conference on the Medical Treatment of Colorectal Cancer – 5-6 July 2007, Vienna
- Curs – Protectia radiologica in radioterapie, 2007
- Conferinta – 17th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists – Colorectal Cancer Treatment in Older Patient – current status, 2007
- Regional Expert from Romania during Global Continuing Education Program for Region 5 – Rodica Anghel, PhMD, the choice of The Organizing Committee of the Conference „Current Concepts in Head and Neck Surgery and Oncology” POLAND, Warsaw, 13-14 October 2008
- The role of anthracycline-based treatment in breast cancer - The CECOG experience .Rodica Anghel, invitated speaker. Central European Cooperative Oncology Group (CECOG) Meeting A Central European Meeting on the “State of the art Treatment” on the Occasion of the 10th Anniversary of the Founding of CECOG 13 – 14 November 2008
- Curs postuniversitar preconferinta Conferinta Societatii Romane de Radioterapie si Zilele Medicale ale Institutului Oncologic Prof. Dr. Al. Trestioreanu Bucuresti – 17-19 septembrie 2009 – Poiana Brasov
- Curs – Protectia radiologica in radioterapie, 2009
- Romanian Representative at the **4-th European Cervical Cancer Meeting** (European Parliament) – Brussel, Belgium, 26-27 January 2010
- GSK Gynaecological Cancers Medical Education Programme – February 19-20, Bratislava, 2010
- Curs – “Advanced Good Clinical Practice for Clinical Research Professionals” – December 2010, The Institute of Clinical Research
- IAEA National Training Course on the implementation of Quality Management Systems in a Radiotherapy Centre 12-14 December 2012 – Bucharest, Romania

- Curs – National Training Course on the implementation of Quality Management Systems in a Radiotherapy Center, Institutul Oncologic Bucuresti, 13 -17 May 2013
- Organizer and Lector of First Summer School in Oncology, "Modern Oncology – State of the Art", 1st - 5th of July 2013, Bucharest, Romania
- Course Director - National Training Course on the Patient Positioning and Immobilisation (Under the IAEA TC Project ROM/6/016) -“Upgrading Radiotherapy Practice at the Oncology Institute Through the Introduction of New Techniques” - 7<sup>th</sup>-8<sup>th</sup> November 2013, Bucharest, Romania
- Organizer/Lector of the Workshop “National Training Course on Target Volume Definition in CNS and H&N Cancers Radiotherapy” Bucharest, 13-15 November 2013
- Lector of 3-rd World Nuclear University (WNU) School on Radiation Technologies – **Radiotherapy: External Beam and Brachytherapy** - Doha, Qatar, 7-20 March 2014
- Organizer and Lector of the Second Summer School in Oncology, "Updated oncology 2014. State of the art news and challenging topics"16-20.06.2014, Bucharest, Romania
- Organizer and Lector of the Third Summer School in Oncology, “Updated Oncology 2015: State of the art news and challenging topics” 15-19 June 2015, Bucharest, Romania
- Organizer and Lector of the Fourth Summer School in Oncology, "Updated Oncology 2016: State of the Art News & Challenging Topics", 13-17 June 2016, Bucharest, Romania
- Organizer and Lector of the Fifth Summer School in Oncology, “Standards and controversies in today’s oncology and immunooncology”, 12-16 June 2017, Bucharest, Romania
- Organizer and Lector of the Sixth Summer School in Oncology, "Facts and controversies in today's oncology", 11 - 15 June 2018, Bucharest, Romania
- Lector: Clinical Cases – Locally Advance SCCHN – Sibiu, 2018
- Noutati si inovatii in tratamentul cancerelor ginecologice – Lector - Conferinta medicilor de familie, Bucuresti, 2018

#### Reviste:

- Membru in colegiul de redactie al JAMA – sectia romana
- Membru in colegiul de redactie a Revistei Societatii Romane de Oncologie
- Membra a colegiului de redactie al revistei Radioterapie si Oncologie Medicala
- Membru al colectivului de redactie al revistei B.U.O.N
- Membru al colectivului editorial al revistei MEMO (Magazine of European Medical oncology)

Lucrari publicate: 44

Monografii publicate: 8

Capitole in carti: 9

Lucrari stiintifice prezentate: 312

Brevete de inventie: 4

Principalele domenii de interes:

- Tratamentul tumorilor cerebrale
- Tratamentul multimodal al tumorilor gastro – intestinale
- Tratamentul tumorilor mamare
- Tratamentul cancerului de prostata
- Tratamentul tumorilor de sfera ORL
- Tratamentul cancerelor sferei genitale

June 28, 2018